These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 29463555

  • 21. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Ku BM, Bae YH, Lee KY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056
    [Abstract] [Full Text] [Related]

  • 22. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
    Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, Raddrizzani L, Palmeri L, Banfi P, Bonazzina E, Misale S, Marrapese G, Leone A, Alzani R, Luo D, Hornby Z, Lim J, Veronese S, Vanzulli A, Bardelli A, Martignoni M, Davite C, Galvani A, Isacchi A, Siena S.
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563355
    [Abstract] [Full Text] [Related]

  • 23. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
    Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S, Bremer NV, Yang SR, Feng Y, Zhou C, Kong N, Liang R, Xu H, Zhang B, Bardelli A, Toska E, Ventura A, Drilon A, Cocco E.
    Br J Cancer; 2024 Aug; 131(3):601-610. PubMed ID: 38902532
    [Abstract] [Full Text] [Related]

  • 24. NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
    Somwar R, Hofmann NE, Smith B, Odintsov I, Vojnic M, Linkov I, Tam A, Khodos I, Mattar MS, de Stanchina E, Flynn D, Ladanyi M, Drilon A, Shinde U, Davare MA.
    Commun Biol; 2020 Dec 16; 3(1):776. PubMed ID: 33328556
    [Abstract] [Full Text] [Related]

  • 25. Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer.
    Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D, Christiansen J, Hornby Z, Maneval EC, Multani P.
    J Natl Compr Canc Netw; 2017 Nov 16; 15(11):1317-1322. PubMed ID: 29118225
    [Abstract] [Full Text] [Related]

  • 26. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
    Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P.
    J Med Chem; 2016 Apr 14; 59(7):3392-408. PubMed ID: 27003761
    [Abstract] [Full Text] [Related]

  • 27. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
    Frampton JE.
    Drugs; 2021 Apr 14; 81(6):697-708. PubMed ID: 33871816
    [Abstract] [Full Text] [Related]

  • 28. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
    Chong CR, Bahcall M, Capelletti M, Kosaka T, Ercan D, Sim T, Sholl LM, Nishino M, Johnson BE, Gray NS, Jänne PA.
    Clin Cancer Res; 2017 Jan 01; 23(1):204-213. PubMed ID: 27370605
    [Abstract] [Full Text] [Related]

  • 29. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.
    Park DY, Choi C, Shin E, Lee JH, Kwon CH, Jo HJ, Kim HR, Kim HS, Oh N, Lee JS, Park OK, Park E, Park J, Shin JY, Kim JI, Seo JS, Park HD, Park J.
    Oncotarget; 2016 Feb 16; 7(7):8399-412. PubMed ID: 26716414
    [Abstract] [Full Text] [Related]

  • 30. MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements.
    Takumi Y, Arai S, Suzuki C, Fukuda K, Nishiyama A, Takeuchi S, Sato H, Matsumoto K, Sugio K, Yano S.
    Cancer Med; 2023 Mar 16; 12(5):5809-5820. PubMed ID: 36416133
    [Abstract] [Full Text] [Related]

  • 31. TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer.
    Sohn SH, Sul HJ, Kim B, Kim BJ, Kim HS, Zang DY.
    J Cancer; 2021 Mar 16; 12(21):6356-6362. PubMed ID: 34659525
    [Abstract] [Full Text] [Related]

  • 32. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
    Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L.
    Expert Opin Investig Drugs; 2015 Mar 16; 24(11):1493-500. PubMed ID: 26457764
    [Abstract] [Full Text] [Related]

  • 33. Entrectinib: First Global Approval.
    Al-Salama ZT, Keam SJ.
    Drugs; 2019 Sep 16; 79(13):1477-1483. PubMed ID: 31372957
    [Abstract] [Full Text] [Related]

  • 34. Targeting TRK family proteins in cancer.
    Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS.
    Pharmacol Ther; 2017 May 16; 173():58-66. PubMed ID: 28174090
    [Abstract] [Full Text] [Related]

  • 35. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
    Rohrberg KS, Lassen U.
    Drugs; 2021 Mar 16; 81(4):445-452. PubMed ID: 33400240
    [Abstract] [Full Text] [Related]

  • 36. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
    Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, Wang L, Hyman DM, Hechtman J, Wei G, Cam NR, Christiansen J, Luo D, Maneval EC, Bauer T, Patel M, Liu SV, Ou SH, Farago A, Shaw A, Shoemaker RF, Lim J, Hornby Z, Multani P, Ladanyi M, Berger M, Katabi N, Ghossein R, Ho AL.
    Ann Oncol; 2016 May 16; 27(5):920-6. PubMed ID: 26884591
    [Abstract] [Full Text] [Related]

  • 37. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
    Iyer R, Wehrmann L, Golden RL, Naraparaju K, Croucher JL, MacFarland SP, Guan P, Kolla V, Wei G, Cam N, Li G, Hornby Z, Brodeur GM.
    Cancer Lett; 2016 Mar 28; 372(2):179-86. PubMed ID: 26797418
    [Abstract] [Full Text] [Related]

  • 38. Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model.
    MacFarland SP, Naraparaju K, Iyer R, Guan P, Kolla V, Hu Y, Tan K, Brodeur GM.
    Mol Cancer Ther; 2020 Mar 28; 19(3):920-926. PubMed ID: 31871269
    [Abstract] [Full Text] [Related]

  • 39. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.
    Regua AT, Bindal S, Najjar MK, Zhuang C, Khan M, Arrigo ABJ, Gonzalez AO, Zhang XR, Zhu JJ, Watabe K, Lo HW.
    Cancer Lett; 2024 Aug 10; 597():217023. PubMed ID: 38852701
    [Abstract] [Full Text] [Related]

  • 40. Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.
    Cook PJ, Thomas R, Kannan R, de Leon ES, Drilon A, Rosenblum MK, Scaltriti M, Benezra R, Ventura A.
    Nat Commun; 2017 Jul 11; 8():15987. PubMed ID: 28695888
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.